| The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis A Tatomir, A Talpos-Caia, F Anselmo, AM Kruszewski, D Boodhoo, V Rus, ... Immunologic research 65, 1103-1109, 2017 | 74 | 2017 |
| Role of SIRT1 in autoimmune demyelination and neurodegeneration A Martin, CA Tegla, CD Cudrici, AM Kruszewski, P Azimzadeh, ... Immunologic research 61, 187-197, 2015 | 70 | 2015 |
| RGC-32 is a novel regulator of the T-lymphocyte cell cycle CA Tegla, CD Cudrici, V Nguyen, J Danoff, AM Kruszewski, D Boodhoo, ... Experimental and molecular pathology 98 (3), 328-337, 2015 | 44 | 2015 |
| SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis D Hewes, A Tatomir, AM Kruszewski, G Rao, CA Tegla, J Ciriello, ... Experimental and Molecular Pathology 102 (2), 191-197, 2017 | 34 | 2017 |
| RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis AM Kruszewski, G Rao, A Tatomir, D Hewes, CA Tegla, CD Cudrici, ... Experimental and molecular pathology 99 (3), 498-505, 2015 | 20 | 2015 |
| SIRT1 as a potential marker of disease activity and response to treatment with Glatiramer Acetate in multiple sclerosis. D Hewes, A Tatomir, AM Kruszewski, J Criello, GK Rao, W Royal III, ... ACTRIMS Forum 2017, 2017 | | 2017 |
| RGC-32 as a potential marker of relapse and response to treatment with glatiramer acetate in multiple sclerosis H Rus, A Kruszewski, C Cudrici, V Nguyen, W Royal, C Bever, V Rus Journal of the Neurological Sciences 357, e17, 2015 | | 2015 |
